Theravance Biopharma (NASDAQ:TBPH) Shares Pass Above 50 Day Moving Average - Should You Sell?

Key Points

• Theravance Biopharma shares have crossed above their 50-day moving average of $14.03, trading as high as $14.59 and last seen at $14.28.
• Analyst ratings are mixed, with the stock receiving two "Strong Buy," two "Buy," and two "Hold" ratings, plus a target price averaging $23.00.
• Hedge funds and institutional investors own a significant 99.10% of Theravance Biopharma's stock, indicating strong institutional support.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $14.03 and traded as high as $14.59. Theravance Biopharma shares last traded at $14.28, with a volume of 220,285 shares trading hands.

Analyst Ratings Changes

TBPH has been the subject of a number of research analyst reports. B. Riley initiated coverage on Theravance Biopharma in a research note on Friday, September 12th. They issued a "buy" rating and a $28.00 target price for the company. Weiss Ratings reissued a "hold (c)" rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. BTIG Research raised their price target on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, June 27th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. Finally, Zacks Research downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Theravance Biopharma currently has an average rating of "Buy" and an average target price of $23.00.

Theravance Biopharma Price Performance

The company has a 50 day moving average price of $14.03 and a two-hundred day moving average price of $11.62. The stock has a market cap of $719.16 million, a PE ratio of 59.50 and a beta of -0.03.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. purchased a new position in shares of Theravance Biopharma in the second quarter worth $264,000. GSA Capital Partners LLP raised its stake in shares of Theravance Biopharma by 11.9% in the first quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company's stock worth $1,628,000 after purchasing an additional 19,363 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Theravance Biopharma in the first quarter worth $419,000. Bank of New York Mellon Corp raised its stake in shares of Theravance Biopharma by 1.5% in the first quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock worth $1,049,000 after purchasing an additional 1,720 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Theravance Biopharma by 121,993.7% in the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.